Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEEBACIN vs NYDRAZID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TEEBACIN is a combination of isoniazid and rifampin. Isoniazid inhibits mycolic acid synthesis in mycobacterial cell wall, while rifampin inhibits bacterial DNA-dependent RNA polymerase.
Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.
Treatment of tuberculosis (first-line therapy in combination with other antituberculosis agents)
Treatment of active tuberculosis (in combination with other antituberculous agents),Prophylaxis of tuberculosis in high-risk individuals
1350 mg orally twice daily with food.
300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; clinical context: reduced dosing interval required in renal impairment (e.g., every 12-24 hours for Cr Cl <30 m L/min)
Terminal elimination half-life: 1-4 hours (fast acetylators), 2-8 hours (slow acetylators). Half-life prolonged in hepatic impairment; adjust dose.
Isoniazid is metabolized primarily by N-acetyltransferase 2 (NAT2) in the liver. Rifampin is metabolized via deacetylation and undergoes extensive enterohepatic circulation; it is a potent inducer of CYP3A4 and other CYP450 enzymes.
Hepatic metabolism primarily via N-acetyltransferase 2 (NAT2) to acetylisoniazid, which is further metabolized to hepatotoxic metabolites.
Primarily renal (80-90% as unchanged drug); minor biliary/fecal elimination (10-20%)
Renal excretion of unchanged drug and metabolites; 50-70% excreted in urine within 24 hours, mainly as acetylisoniazid and isonicotinic acid. Biliary/fecal: <10%.
10-20% bound, primarily to albumin
10-20% bound primarily to albumin; binding is low and clinically insignificant.
0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid
Vd: 0.6-0.8 L/kg; distributes into total body water, including CSF, pleural fluid, and caseous granulomas.
Oral: 75-90%; bioavailability decreases with food intake
Oral: 90-100% (fasting). Food may decrease absorption by 20-50%; take on empty stomach.
GFR ≥60 m L/min: no adjustment; GFR 30-59: 1350 mg once daily; GFR 15-29: 1350 mg every 48 hours; GFR <15 or dialysis: not recommended.
If GFR < 30 m L/min: administer 200 mg once daily or 300 mg three times weekly. For severe renal impairment (GFR < 10 m L/min) or hemodialysis: 200 mg daily or 300 mg three times weekly, given after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: 1350 mg once daily; Child-Pugh C: not recommended.
Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 50% (e.g., 150 mg daily). Child-Pugh Class C: reduce dose by 50-75% (e.g., 100-150 mg daily) or consider alternative therapy; monitor liver function closely.
Not established; safety and efficacy not evaluated.
For latent tuberculosis: 10-15 mg/kg (max 300 mg) orally once daily for 6-9 months. For active tuberculosis: 10-15 mg/kg (max 300 mg) orally once daily for 2 months, then 15 mg/kg (max 900 mg) orally three times weekly for 4-7 months.
Start at 1350 mg once daily; monitor renal function; increase to twice daily if tolerated and Cr Cl ≥60 m L/min.
Start at lower end of dosing range (e.g., 200-300 mg daily) due to potential renal impairment; monitor liver function and signs of hepatotoxicity; adjust dose based on creatinine clearance if GFR < 30 m L/min.
Severe and sometimes fatal hepatitis has been reported with isoniazid. Risk is increased in patients with pre-existing liver disease, daily alcohol use, or concurrent use of other hepatotoxic drugs.
Severe and sometimes fatal hepatitis has been reported, even after months of treatment. Risk increases with age, daily alcohol use, and pre-existing liver disease. Monitor liver function tests closely.
Hepatotoxicity (monitor liver function); peripheral neuropathy (pyridoxine supplementation recommended); hypersensitivity reactions; rifampin may cause reddish discoloration of body fluids; drug interactions due to CYP450 induction.
Peripheral neuropathy (prevent with pyridoxine), hepatotoxicity, hypersensitivity reactions (e.g., fever, rash), lupus-like syndrome, seizures, optic neuritis, drug interactions (e.g., phenytoin, carbamazepine, disulfiram).
Hypersensitivity to isoniazid, rifampin, or any component; severe hepatic damage; acute liver disease; history of isoniazid-associated hepatotoxicity.
Severe hepatic disease, acute liver disease, or previous isoniazid-associated hepatitis; hypersensitivity to isoniazid or any component.
Avoid high-tyramine foods (aged cheeses, cured meats, fermented products) as it may cause hypertensive crisis. Take with food to reduce gastrointestinal upset. Avoid tyramine-rich foods like soy products and sauerkraut.
Isoniazid inhibits monoamine oxidase (MAO) and reduces metabolism of tyramine, leading to hypertensive crisis. Avoid tyramine-rich foods: aged cheeses (cheddar, blue cheese), cured or fermented meats (salami, pepperoni, pickled herring), soy products (tofu, miso, tempeh), sauerkraut, fava beans, tap beers, and red wines. Also avoid foods containing histamine (tuna, mackerel, sauerkraut). Concomitant alcohol consumption increases risk of hepatotoxicity and should be strictly avoided. High-protein meals or dairy may interfere with absorption; maintain consistent timing relative to meals. There is no restriction on carbohydrates or fats.
TEEBACIN is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects based on animal studies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment due to drug-induced vasoconstriction.
Isoniazid (INH) is not associated with major congenital malformations in humans. However, in vivo animal studies have shown embryocidal effects at high doses. The drug is considered safe during all trimesters; however, due to the risk of hepatotoxicity, monitoring of liver function is recommended, especially in the third trimester. Perinatal exposure increases the risk of neonatal hemorrhage due to vitamin K deficiency, which can be prevented by prophylactic vitamin K administration to the mother.
Unknown if TEEBACIN is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, including immunosuppression and growth retardation, breastfeeding is not recommended. M/P ratio not available.
Isoniazid is excreted into breast milk in concentrations similar to maternal plasma. The milk-to-plasma (M/P) ratio is approximately 1.0. The American Academy of Pediatrics considers it compatible with breastfeeding. However, due to the theoretical risk of hepatotoxicity and peripheral neuropathy in the infant, monitoring of the infant for signs of jaundice, hepatitis, or neuropathy is recommended. The dose to the infant is subtherapeutic (about 0.5-2% of the maternal dose) and is unlikely to cause adverse effects.
No dosing recommendations for use in pregnancy as drug is contraindicated. If used inadvertently, pharmacokinetic changes include increased renal clearance in later pregnancy, which may reduce drug exposure. However, due to teratogenicity, no dose adjustment is advised; immediate discontinuation upon pregnancy detection is recommended.
Standard dosing of isoniazid (300 mg daily or 900 mg twice weekly) is generally recommended during pregnancy. No dose adjustment is required as pregnancy does not significantly alter the pharmacokinetics of isoniazid. However, due to increased hepatic metabolism in pregnancy, some experts recommend monitoring serum drug levels to ensure therapeutic concentrations, though routine monitoring is not standard. Pyridoxine (25-50 mg daily) should be co-administered to prevent peripheral neuropathy in the mother and fetus.
Monitor liver function tests (ALT, AST) monthly due to risk of hepatotoxicity. Avoid use in patients with porphyria as it may precipitate acute attacks. Contraindicated in pregnancy (Pregnancy Category X). Administer with pyridoxine (vitamin B6) to reduce peripheral neuropathy risk.
NYDRAZID (isoniazid) is a first-line antitubercular agent. Always prescribe pyridoxine (vitamin B6) 25-50 mg daily to prevent peripheral neuropathy, especially in patients with risk factors like diabetes, alcoholism, malnutrition, or HIV. Monitor liver function tests closely; hepatotoxicity risk increases with age >35, concurrent use of acetaminophen or other hepatotoxic drugs, and pre-existing liver disease. Slow acetylators (genetic) have higher risk of toxicity. Isoniazid can cause bilateral optic neuritis; monitor for visual symptoms. Drug interactions: increases levels of phenytoin, carbamazepine, and theophylline; reduce doses accordingly. Administer on empty stomach (1 hour before or 2 hours after meals) for optimal absorption. In case of overdose, high-dose pyridoxine is antidote (1 g per gram of isoniazid ingested).
Take this medication exactly as prescribed; do not skip doses or stop early without consulting your doctor.,Avoid alcohol completely while taking this drug due to increased risk of liver damage.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe nausea/vomiting, or abdominal pain.,Use effective contraception if you are of childbearing age; this drug can cause severe birth defects.,Take vitamin B6 supplements as directed to help prevent numbness or tingling in hands and feet.
Take isoniazid on an empty stomach with a full glass of water, at least 1 hour before or 2 hours after meals.,Do not drink alcohol while taking this medication; combined with alcohol increases risk of severe liver damage.,Take vitamin B6 (pyridoxine) exactly as prescribed to prevent nerve damage.,Report immediately: dark urine, pale stools, yellowing of skin or eyes, nausea/vomiting, abdominal pain, unusual fatigue (liver toxicity signs).,Report numbness, tingling, or burning in hands/feet; vision changes; rash; or fever.,Avoid foods high in tyramine (aged cheese, cured meats, soy products, tap beer) while taking isoniazid; may cause hypertensive crisis.,Take all doses on schedule; do not skip or stop without consulting provider.,Keep all follow-up appointments for blood tests to monitor liver function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEEBACIN vs NYDRAZID, answered by our medical review team.
TEEBACIN is a Antitubercular agent that works by TEEBACIN is a combination of isoniazid and rifampin. Isoniazid inhibits mycolic acid synthesis in mycobacterial cell wall, while rifampin inhibits bacterial DNA-dependent RNA polymerase.. NYDRAZID is a Antitubercular Agent that works by Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEEBACIN and NYDRAZID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEEBACIN is: 1350 mg orally twice daily with food.. The standard adult dose of NYDRAZID is: 300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEEBACIN and NYDRAZID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEEBACIN is classified as Category C. TEEBACIN is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial de. NYDRAZID is classified as Category C. Isoniazid (INH) is not associated with major congenital malformations in humans. However, in vivo animal studies have shown embryocidal effects at high doses. The drug is considere. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.